Beutel, Goodman & Co’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Beutel, Goodman & Co’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32.3M	Sell	3,529,124 -98,740	-3%	-$702K	0.25%	60
2026 Q2	$23.8M	Sell	3,627,864 -38,601	-1%	-$266K	0.18%	64
2026 Q1	$26.4M	Sell	3,666,465 -42,908	-1%	-$345K	0.18%	62
2025 Q4	$27.9M	Sell	3,709,373 -349,526	-9%	-$2.15M	0.17%	56
2025 Q3	$23.9M	Buy	+4,058,899	New	+$22.1M	0.14%	56

Other funds holding EPRX

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

TCI Wealth Advisors Tucson, Arizona $2.49B AUM 17.07% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Beutel, Goodman & Co's EPRX Position: Q3 2026 in Review

Beutel, Goodman & Co reduced its Eupraxia Pharmaceuticals (EPRX) stake by 2.7% in Q3 2026, selling an estimated $702K and leaving 3,529,124 shares worth $32.3M. The position accounts for 0.25% of the portfolio, ranked #60.

Beutel, Goodman & Co first reported a position in EPRX in Q3 2025 and has held it in 5 quarters since. 6 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

Beutel, Goodman & Co held 3,529,124 shares of Eupraxia Pharmaceuticals worth $32.3M as of Q3 2026.
Beutel, Goodman & Co sold 98,740 Eupraxia Pharmaceuticals shares in Q3 2026, an estimated $702K.
Eupraxia Pharmaceuticals made up 0.25% of Beutel, Goodman & Co's portfolio in Q3 2026, its #60 holding.
Beutel, Goodman & Co first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
6 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Beutel, Goodman & Co's 13F filing for Q3 2026, filed 4 Nov 2026.